Homologous polydopamine ameliorates haemolysis of melittin for enhancing its anticancer efficacy-Reference-Cited by-同舟云学术

Homologous polydopamine ameliorates haemolysis of melittin for enhancing its anticancer efficacy

Published:2024 Issue:22 Volume:12 Page:5431-5438
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Zheng Yuhan¹,Wei Qingyun²,Han Xuan¹,Tao Xiangmin¹,Cao Tao¹^ORCID,Chen Tianbao³,Cao Peng¹²⁴⁵,Zhan Qichen¹^ORCID

Affiliation:

1. Animal-Derived Chinese Medicine and Functional Peptides International Collaboration Joint Laboratory, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China

2. Jiangsu Provincial Medicinal Innovation Centre, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, China

3. Natural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast, UK

4. Shandong Academy of Chinese Medicine, Jinan 250014, China

5. The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou Peoples Hospital, Quzhou 324000, China

Abstract

Despite exhibiting potent anticancer activity, the strong hemolytic properties of melittin (MEL) significantly restrict its delivery efficiency and clinical applications.

Funder

National Natural Science Foundation of China

Nanjing University of Chinese Medicine

Graduate Research and Innovation Projects of Jiangsu Province

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/TB/D4TB00002A

Reference35 articles.

1. American Cancer Society's report on the status of cancer disparities in the United States, 2021

2. Immunomodulating Nanomedicine for Cancer Therapy

3. Tricyclic cell-penetrating peptides for efficient delivery of functional antibodies into cancer cells

4. Cell-penetrating peptides in protein mimicry and cancer therapeutics

5. Delivery Strategies for Melittin-Based Cancer Therapy